Rigel Pharmaceuticals

Performance

About Rigel Pharmaceuticals

Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and delivering novel therapies to improve the lives of patients with hematologic disorders and cancer. The company operates in the United States, with a base in South San Francisco, California, and emphasizes small molecule drug development across immune and oncology indications. Rigel’s pipeline includes targeted assets such as IRAK1/4 inhibitors, RIPK1 inhibitors, IDH1-related programs, and other partnered assets. The organization also highlights pursuing investigator-sponsored research and expanded access programs as part of its clinical and development efforts.